Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TNYA |
---|---|---|
09:32 ET | 5092 | 1.98 |
09:34 ET | 5740 | 1.92 |
09:36 ET | 6480 | 1.91 |
09:38 ET | 1100 | 1.96 |
09:41 ET | 900 | 1.955 |
09:45 ET | 1400 | 1.96 |
09:48 ET | 100 | 1.965 |
09:50 ET | 300 | 1.98 |
09:52 ET | 500 | 2 |
09:57 ET | 338 | 2 |
10:01 ET | 200 | 1.98 |
10:03 ET | 500 | 1.98 |
10:06 ET | 100 | 1.98 |
10:08 ET | 100 | 1.985 |
10:10 ET | 1605 | 2 |
10:12 ET | 100 | 1.99 |
10:14 ET | 100 | 1.98 |
10:17 ET | 5297 | 1.985 |
10:19 ET | 1580 | 1.98 |
10:21 ET | 5000 | 1.98 |
10:26 ET | 13009 | 1.96 |
10:30 ET | 100 | 1.965 |
10:32 ET | 3443 | 1.975 |
10:33 ET | 132 | 1.976 |
10:35 ET | 2800 | 1.975 |
10:39 ET | 3200 | 1.975 |
10:42 ET | 5100 | 1.99 |
10:44 ET | 3200 | 1.98 |
10:46 ET | 500 | 1.98 |
10:51 ET | 300 | 1.97 |
10:53 ET | 100 | 1.99 |
10:55 ET | 500 | 1.99 |
10:57 ET | 200 | 1.9983 |
11:00 ET | 2167 | 2 |
11:02 ET | 700 | 1.99 |
11:04 ET | 100 | 1.98 |
11:08 ET | 526 | 1.99 |
11:11 ET | 1300 | 2 |
11:13 ET | 100 | 1.98 |
11:20 ET | 100 | 2 |
11:22 ET | 200 | 2 |
11:24 ET | 100 | 2 |
11:26 ET | 100 | 2 |
11:29 ET | 200 | 1.98 |
11:33 ET | 100 | 2 |
11:36 ET | 4945 | 2 |
11:38 ET | 100 | 1.99 |
11:40 ET | 320 | 2 |
11:47 ET | 200 | 1.99 |
11:49 ET | 200 | 2.01 |
11:51 ET | 324 | 2.01 |
11:54 ET | 300 | 2 |
11:56 ET | 100 | 2 |
11:58 ET | 100 | 1.99 |
12:05 ET | 1102 | 1.98 |
12:12 ET | 100 | 2 |
12:14 ET | 200 | 1.98 |
12:18 ET | 1000 | 1.98 |
12:25 ET | 300 | 1.968 |
12:27 ET | 100 | 1.96 |
12:38 ET | 438 | 1.96 |
12:43 ET | 500 | 1.96 |
12:45 ET | 100 | 1.98 |
12:48 ET | 100 | 1.96 |
12:50 ET | 100 | 1.98 |
12:52 ET | 150 | 1.978 |
12:54 ET | 282 | 1.9783 |
12:56 ET | 250 | 1.97 |
12:59 ET | 1822 | 1.9437 |
01:03 ET | 150 | 1.9647 |
01:06 ET | 100 | 1.96 |
01:10 ET | 100 | 1.94 |
01:12 ET | 564 | 1.9699 |
01:19 ET | 100 | 1.94 |
01:21 ET | 100 | 1.94 |
01:26 ET | 4937 | 1.955 |
01:30 ET | 400 | 1.954 |
01:32 ET | 3500 | 1.95 |
01:33 ET | 300 | 1.95 |
01:37 ET | 400 | 1.96 |
01:42 ET | 100 | 1.97 |
01:46 ET | 100 | 1.965 |
01:50 ET | 1830 | 1.97 |
02:06 ET | 1600 | 1.98 |
02:09 ET | 100 | 1.985 |
02:15 ET | 1187 | 1.98 |
02:20 ET | 200 | 1.97 |
02:27 ET | 100 | 1.96 |
02:33 ET | 300 | 1.9607 |
02:38 ET | 1000 | 1.97 |
02:40 ET | 5000 | 1.9797 |
02:44 ET | 300 | 1.975 |
02:45 ET | 423 | 1.97 |
02:49 ET | 100 | 1.97 |
02:58 ET | 118 | 1.964 |
03:00 ET | 300 | 1.96 |
03:02 ET | 300 | 1.96 |
03:03 ET | 242 | 1.96 |
03:07 ET | 100 | 1.95 |
03:14 ET | 3016 | 1.96 |
03:20 ET | 100 | 1.95 |
03:21 ET | 100 | 1.95 |
03:23 ET | 615 | 1.95 |
03:27 ET | 100 | 1.95 |
03:30 ET | 300 | 1.95 |
03:34 ET | 200 | 1.95 |
03:36 ET | 456 | 1.95 |
03:38 ET | 200 | 1.96 |
03:39 ET | 100 | 1.95 |
03:41 ET | 2000 | 1.9686 |
03:45 ET | 5801 | 1.965 |
03:48 ET | 103 | 1.965 |
03:50 ET | 1100 | 1.965 |
03:52 ET | 4250 | 1.97 |
03:54 ET | 1100 | 1.96 |
03:56 ET | 1950 | 1.97 |
03:57 ET | 4772 | 1.955 |
03:59 ET | 54914 | 1.97 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tenaya Therapeutics Inc | 155.8M | -1.3x | --- |
Context Therapeutics Inc | 156.0M | -1.8x | --- |
Achieve Life Sciences Inc | 150.4M | -3.9x | --- |
Inovio Pharmaceuticals Inc | 152.5M | -1.2x | --- |
Immunic Inc | 144.1M | -1.0x | --- |
Invivyd Inc | 143.3M | -0.6x | --- |
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $155.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 78.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.54 |
Book Value | $2.04 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.